Detalles de la búsqueda
1.
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
N Engl J Med
; 386(4): 316-326, 2022 01 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-35081280
2.
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial.
Ann Rheum Dis
; 82(3): 331-343, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36600185
3.
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance.
Ann Rheum Dis
; 82(1): 119-129, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36137735
4.
Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial.
Ann Rheum Dis
; 81(11): 1491-1503, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35922124
5.
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. Reply.
N Engl J Med
; 386(18): 1768, 2022 05 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35507493
6.
Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study.
Clin Exp Rheumatol
; 38(5): 848-857, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-31858963
7.
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme.
Ann Rheum Dis
; 82(4): 575-577, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36720582
8.
Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry.
Ann Rheum Dis
; 80(1): 134-136, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33046447
9.
Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.
N Engl J Med
; 367(6): 495-507, 2012 Aug 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-22873530
10.
Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study.
Ann Rheum Dis
; 73(1): 124-31, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23482473
11.
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.
Arthritis Rheum
; 65(3): 559-70, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23348607
12.
Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study.
RMD Open
; 10(2)2024 Apr 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38609322
13.
Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk-Enriched Rheumatoid Arthritis Patients.
Arthritis Rheumatol
; 2024 Mar 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38481002
14.
A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.
Arthritis Rheum
; 64(4): 970-81, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22006202
15.
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.
Arthritis Rheum
; 64(3): 617-29, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-21952978
16.
Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance.
Ther Adv Musculoskelet Dis
; 15: 1759720X231201047, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37942277
17.
Fracture in clinical studies of tofacitinib in rheumatoid arthritis.
Ther Adv Musculoskelet Dis
; 14: 1759720X221142346, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36601090
18.
Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals.
Eur J Drug Metab Pharmacokinet
; 47(3): 419-429, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35226304
19.
Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry.
ACR Open Rheumatol
; 3(3): 173-184, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33570260
20.
Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib.
RMD Open
; 5(1): e000742, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30886732